



SEQUENCE LISTING

<110> Schering AG

<120> New Effector-Conjugates, Methods for Their Preparation and Their Pharmaceutical Use

<130> SCH10522US

<140> US 10/631,011

<141> 2003-07-31

<160> 1

<170> Word for Windows

<210> 1

<211> 241

<212> Prt

<213> Homo sapiens

<220>

<223> anti-(ED-B) scFV Antibody fragment; Name: AP39

<400>

Glu	Val	Gln	Leu	Leu	Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln	Pro	Gly	1	5	10	15
Gly	Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe	Ser	20	25	30	35
Ser	Phe	Ser	Met	Ser	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	40	45	50	55
Glu	Trp	Val	Ser	Ser	Ile	Ser	Gly	Ser	Ser	Gly	Thr	Thr	Tyr	Tyr	60	65	70	75
Ala	Asp	Ser	Val	Lys	Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asn	Ser	80	85	90	95
Lys	Asn	Thr	Leu	Tyr	Leu	Gln	Met	Asn	Ser	Leu	Arg	Ala	Glu	Asp	100	105	110	115
Thr	Ala	Val	Tyr	Tyr	Cys	Ala	Lys	Pro	Phe	Pro	Tyr	Phe	Asp	Tyr	120	125	130	135
Trp	Gly	Gln	Gly	Thr	Leu	Val	Thr	Val	Ser	Ser	Gly	Asp	Gly	Ser	140	145	150	155
Ser	Gly	Gly	Ser	Gly	Gly	Ala	Ser	Glu	Ile	Val	Leu	Thr	Gln	Ser	160	165	170	175
Pro	Gly	Thr	Leu	Ser	Leu	Ser	Pro	Gly	Glu	Arg	Ala	Thr	Leu	Ser	180	185	190	195
Cys	Arg	Ala	Ser	Gln	Ser	Val	Ser	Ser	Ser	Phe	Leu	Ala	Trp	Tyr	200	205	210	215
Gln	Gln	Lys	Pro	Gly	Gln	Ala	Pro	Arg	Leu	Leu	Ile	Tyr	Tyr	Ala	220	225	230	235
Ser	Ser	Arg	Ala	Thr	Gly	Ile	Pro	Asp	Arg	Phe	Ser	Gly	Ser	Gly	240			
Ser	Gly	Thr	Asp	Phe	Thr	Leu	Thr	Ile	Ser	Arg	Leu	Glu	Pro	Glu				
Asp	Phe	Ala	Val	Tyr	Tyr	Cys	Gln	Gln	Thr	Gly	Arg	Ile	Pro	Pro				
Thr	Phe	Gly	Gln	Gly	Thr	Lys	Val	Glu	Ile	Lys	Gly	Gly	Gly	Cys				
Ala																		